In reply: We agree with Johnson and Lassere about the value of longitudinal studies, especially clinical trials, in assessing healthcare benefits and costs. They are critical to informing clinical practice and health policy.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
Correspondence:
- 1. Liew D, McNeil JJ, Peeters A, et al. Epidemiological modelling (including economic modelling) and its role in preventive drug therapy. Med J Aust 2002; 177: 364-367. <eMJA full text>
Online responses are no longer available. Please refer to our instructions for authors page for more information.